Ovarian Cancer Clinical Trials
Ovarian Cancer
Learn More About Ovarian Cancer
For general information on ovarian cancer (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| DCSZ11-101 | Ovarian Cancer | A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Immunotherapy | Anti-CD93 monoclonal antibody, as a monotherapy and in combination with pembro. | Closed | DynamiCure Biotechnology | NCT05785754 | Enquire Now |
| MTX-TROP2-302 | Ovarian Cancer | MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors | Immunotherapy | TROP2 targeting. Low volume disease only. | Closed | Myeloid Therapeutics | NCT05969041 | Enquire Now |
| ADCE-T02-01 | Ovarian Cancer | First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting a tissue factor. | Open - Recruiting | Adcendo ApS | NCT06597721 | Enquire Now |
| CP-IVX001 | Ovarian Cancer | A Phase 1 Open-label, Non-randomized, Multi-cohort Clinical Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Injectable Lesions | Ovarian, Gastric and CRC only. Must have Injectable lesions. Intratumoral injection. Live EchoVirus, No GMO component. | Open - Recruiting | ImmVirx PtyLtd | NCT05427487 | Enquire Now |
| DM002001 | Ovarian Cancer | A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors | Antibody Drug Conjugate | ADC targeting MUC1 and HER3 | Open - Recruiting | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | NCT06751329 | Enquire Now |